Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. | The ...

Essential tremor (ET) is a brain condition that causes uncontrollable shaking of the hands, head, and voice. In some cases, it can also cause your legs and trunk to shake. Also called benign essential ...

Essential tremor (ET), a neurological disorder characterized by involuntary, rhythmic shaking of the hands and head, is one of the most common movement disorders, affecting an estimated 2.2% of the ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. are soaring, boosted by the successful trial of a new ...

Ulixacaltamide is a highly selective small molecule T-type calcium channel inhibitor designed to block neuronal bursting in the cerebello-thalamo-cortical circuit linked to tremor activity.

Essential tremor is the most common movement disorder in the world—10 times more common than Parkinson's disease. This progressive condition involves tremor of the hands and in some cases can ...

Treatment options for essential tremor include medications, exercises, lifestyle changes, and in severe cases, surgical procedures such as deep brain stimulation. Essential tremor is a neurological ...

Ben Duncan’s doctor asked him to draw a spiral on a sheet of notebook paper. Tremors sent his hand shaking and scribbling all over the page as he tried to draw. What was left on the paper told the ...

Shares of the Boston company, which closed Wednesday at $57.35, were recently up 109% to $119.83. Praxis said the two Phase 3 studies of ulixacaltamide met their primary endpoints in essential tremor, ...